JNJ — Johnson & Johnson stock price, charts and financials

QT71Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
260.04
+0.80+0.31%
OverviewShort InterestFilings
JNJQT71Johnson & Johnson·NYSE
260.04+0.31%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ABBV+0.22%$246.58LLY+3.60%$1228.44MRK+1.65%$130.70NVS+0.22%$156.68AZN+0.18%$161.71AMGN+0.85%$414.45NVO+0.40%$47.45GILD-0.40%$132.68
Snapshot
IndexS&P 500, DJIAP/E29.97EPS (ttm)8.65Insider Own0.06%Shs Outstand2.41BPerf Week1.13%
Market Cap624.74BForward P/E20.24EPS next Y12.81Insider Trans-21.92%Shs Float2.41BPerf Month0.05%
Enterprise Value653.36BPEG-EPS next Q3.04Inst Own68.20%Short Float1.14%Perf Quarter16.51%
Income20.80BP/S6.38EPS this Y34.65%Inst Trans-Short Ratio3.36Perf Half Y9.02%
Sales97.93BP/B7.44EPS next Y10.21%ROA10.46%Short Interest27.43MPerf YTD25.27%
Book/sh-P/C26.69EPS next 5Y11.49%ROE25.74%52W High275.76 -5.70%Perf Year51.97%
Cash/sh-P/FCF33.39EPS past 3/5Y17.90% 14.89%ROIC13.89%52W Low170.44 52.57%Perf 3Y52.57%
Dividend Est.5.36 (2.06%)EV/EBITDA20.47Sales past 3/5Y5.60% 2.67%Gross Margin70.45%Volatility2.19% 2.25%Perf 5Y50.55%
Dividend TTM5.24 (2.02%)EV/Sales6.67EPS Y/Y TTM49.05%Oper. Margin26.81%ATR (14)6.15Perf 10Y108.29%
Dividend Ex-DateAug 25, 2026Quick Ratio0.81Sales Y/Y TTM10.25%Profit Margin21.48%RSI (14)55.45Recom2.55
Dividend Gr. 3/5Y4.92% 5.25%Current Ratio1.09EPS Q/Q4.69%SMA201.01%Beta0.22Target Price282.08
Payout59.99%Debt/Eq0.58Sales Q/Q6.60%SMA504.65%Rel Volume0.76Prev Close259.24
Employees141,700LT Debt/Eq0.48EarningsOct 13SMA20013.68%Avg Volume8.24MPrice260.04
IPO DateJan 02, 1962Option/ShortYes / YesEPS/Sales Surpr.1.59% 0.99%Net Debt/EBITDA0.90Volume6,264,856Change0.31%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedGuggenheimBuy$270 → $287
Aug-03-26ReiteratedRaymond JamesOutperform$265 → $280
Aug-03-26ReiteratedWells FargoOverweight$272 → $282
Jul-29-26ReiteratedArgus ResearchBuy$290 → $300
Jul-16-26ReiteratedJohnson Rice$261 → $280
Jul-16-26ReiteratedScotiabankSector Outperform$265 → $305
Jul-16-26ReiteratedGoldman SachsBuy$275 → $282
Jul-16-26ReiteratedWells FargoOverweight$240 → $272
Jul-16-26ReiteratedRaymond JamesOutperform$209 → $265
Jul-16-26ReiteratedMorgan StanleyOverweight$284 → $294
Latest News
Aug-08-26
Aug-08-2612:00PM
Why PG, JNJ, and KO Could Surprise Investors Next Year247wallst.com
Aug-07-26
Aug-07-2612:46PM
Johnson & Johnson (JNJ) Could Be a Great Choicezacks.com
03:53AM
Armstrong Henry H Associates Inc. Has $82 Million Holdings in Johnson & Johnson $JNJdefenseworld.net
Aug-06-26
Aug-06-2604:35PM
How to Build $8,500 a Month in Dividend Income Without Selling a Single Share247wallst.com
02:02PM
Johnson & Johnson Is Spending $1 Billion to Make More Contact Lenses. Medicare Covers Them in Only One Narrow Situation.247wallst.com
10:15AM
Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.fool.com
07:00AM
5 Solid Dividend Stocks to Buy in August247wallst.com
04:44AM
The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulencefool.com
03:13AM
Avior Wealth Management LLC Sells 4,587 Shares of Johnson & Johnson $JNJdefenseworld.net
Aug-05-26
Aug-05-2605:11PM
The Dividend Income Illusion: Why Your 8% Yield Is Really Paying You 5%247wallst.com
07:01AM
3 Dividend Stocks Built for Retirement to Buy in August247wallst.com
05:10AM
Dividends vs. an Annuity: Which Turns $675,000 Into More Monthly Income for Life?247wallst.com
Aug-04-26
Aug-04-2607:43PM
How Much Do You Really Need Invested to Replace a $100,000 Salary With Dividends?247wallst.com
07:23PM
The $85 Billion Consolation Prize For JNJ ShareholdersYahoo
04:05PM
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conferencebusinesswire.com
Company

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Ownership
Total institutional ownership68.20%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
1/1/2023
FY 2021
1/2/2022
FY 2020
1/3/2021
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue97,92994,19388,821——————
Cost of Goods Sold Incl. D&A28,93625,63527,471——————
Gross Profit68,99368,55861,350——————
Selling, General and Administrative Excl. Other25,14123,67621,969——————
Research and Development15,10414,66517,232——————
Other Operating Expense2,4924,6210——————
Operating Income26,25625,59622,149——————
Interest Expense793971755——————
Unusual Expense
—————————
Non-Operating Income (Expense)-2677,956-4,707——————
Net Income Before Taxes25,19632,58116,687——————
Income Taxes4,1595,7772,621——————
Consolidated Net Income21,03726,80414,066——————
Net Income From Continuing Operations21,03726,80414,066——————
Net Income21,03726,80414,066——————
EPS (Recurring)8.6511.035.84——————
EPS (Basic, Before Extraordinaries)8.6511.035.84——————
EPS (Diluted)8.6311.035.79——————
EBITDA31,91941,05524,781——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio30.1318.8225.05——————
Price To Sales Ratio6.485.353.93——————
Gross Margin70.4572.7869.07——————
Operating Margin26.8127.1724.94——————
Net Margin21.4828.4615.84——————
Shares Outstanding2,4402,4292,407——————
Market Capitalization634,498504,333349,135——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$284.86$246.69$208.51$170.34$132.17● Close Price0.00M13.27M26.54M39.81M53.08MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Forminard ElizabethEVP, Chief Legal OfficerAug 06 '26Sale257.0015,9184,090,96016,994Aug 07
Forminard ElizabethEVP, Chief Legal OfficerAug 06 '26Option Exercise131.949,3441,232,84732,912Aug 07
Duato JoaquinCEO and Chairman of the BoardAug 05 '26Sale258.1548,48012,515,010275,967Aug 07
Broadhurst VanessaEVP, Global Corp AffairsJul 20 '26Option Exercise130.7723,0543,014,70246,057Jul 21
Broadhurst VanessaEVP, Global Corp AffairsJul 20 '26Sale251.2723,0545,792,68623,003Jul 21
Wengel Kathryn EEVP, Chief TO and Risk OfficerJun 11 '26Sale241.1510,0002,411,500114,288Jun 12
Wengel Kathryn EEVP, Chief TO and Risk OfficerJun 11 '26Option Exercise115.6710,0001,156,700124,288Jun 12
REED JOHN CEVP, Innovative Medicine, R&DMay 01 '26Option Exercise0.0025,255035,913May 04
Decker Robert JVP Corporate ControllerFeb 27 '26Sale247.874,0751,010,07023,682Mar 03
Decker Robert JVP Corporate ControllerFeb 27 '26Option Exercise115.674,075471,35527,757Mar 03
Schmid TimothyEVP, WW Chair, MedTechFeb 20 '26Sale245.661,322324,76325,447Feb 23
Schmid TimothyEVP, WW Chair, MedTechFeb 18 '26Sale244.3322,6235,527,50626,769Feb 18
Schmid TimothyEVP, WW Chair, MedTechFeb 18 '26Option Exercise121.1722,6232,741,33540,394Feb 18
REED JOHN CEVP, Innovative Medicine, R&DFeb 17 '26Option Exercise156.8951,6488,103,28142,868Feb 18
Wolk Joseph JExec VP, CFOFeb 17 '26Sale242.8089,65421,767,82714,000Feb 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.